Clinical Trial Outcomes for Advanced HIV Patients in Uganda

A collection of results from a cluster randomized trial of 1,724 participants with advanced HIV disease in Uganda, comparing the Visitect CD4 point-of-care test to standard laboratory-based CD4 testing. The study measured 24-week survival, retention-in-care, time to antiretroviral therapy initiation, and a micro-costing analysis over a six-month period from May 2022 to February 2025.

Use Cases

• Compare 24-week survival and retention-in-care rates between the Visitect CD4 and standard CD4 testing arms.
• Analyze the time to antiretroviral therapy initiation, which was a median of 0 days for Visitect versus 7 days for standard testing.
• Evaluate the cost difference in six-month care, with a mean of US$115 for Visitect CD4 testing versus US$131 for standard-of-care.
• Assess the hazard ratio for the composite endpoint of death or lost to follow-up between the two testing methodologies.

Strengths

• Data from a substantial clinical trial with 1,724 enrolled participants.
• Includes a detailed micro-costing analysis for each trial participant over a six-month period.
• Results are based on a cluster randomized design conducted across 16 outpatient HIV clinics in Uganda.

Limitations

• The trial's randomization was stopped early in June 2024, which may limit the interpretation of long-term comparative effectiveness.
• Specific column definitions and raw data structure are not provided in the input, limiting immediate analytical utility.
• The dataset focuses on a single country (Uganda), which may limit generalizability to other settings with different healthcare infrastructures.

Provenance

Source

Elizabeth Nalintya, Uganda-Minnesota Research Collaboration, via Dataverse.

Collection Method

Data collected as part of a cluster randomized clinical trial.

Time Range

May 5, 2022 to February 18, 2025.

Freshness

Data was last updated on February 5, 2026, and covers a study period ending February 18, 2025.

Geography

16 outpatient HIV clinics in Uganda.